secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000719135-23-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q2 revenue up 32% to $13.6M, net loss narrows 82% to $1.0M, reaffirms FY2023 guide
--------------------------------------------------------------------------------

- Advanced Energy revenue rose 40% YoY to $11.7M; OEM revenue fell 4% to $1.8M.
- Net loss improved to $1.0M ($0.03 loss per share) from $5.4M in Q2 2022.
- Adjusted EBITDA loss decreased 52% to $1.6M; gross margin expanded to 68.4%.
- FY2023 outlook reaffirmed: total revenue $59-62M, Advanced Energy $51-54M, net loss ~$10.5M.
- Completed sale-leaseback of Clearwater facility, netting ~$6.6M; received two FDA 510(k) clearances in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000071913523000045/0000719135-23-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000071913523000045/apyx-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000719135-23-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer